MegaSporeBiotic

MegaSporeBiotic is the first all-spore, pharmaceutical grade probiotic that survives the gastric environment naturally. It is a foundational nutritional food that provides true probiotic benefits.

MegaSporeBioticTM introduces HU36TM, the first commercially available carotenoid rich probiotic. This strain naturally produces forms of lycopene, astaxanthin, zeaxanthin, beta carotene and lutein in your digestive tract right at the site of absorption. This makes them the most bioavailable antioxidants known to science.

$45.50

Description

MegaSporeBiotic is the first all-spore, pharmaceutical grade probiotic that survives the gastric environment naturally. It is a foundational nutritional food that provides true probiotic benefits.

MegaSporeBioticTM introduces HU36TM, the first commercially available carotenoid rich probiotic. This strain naturally produces forms of lycopene, astaxanthin, zeaxanthin, beta carotene and lutein in your digestive tract right at the site of absorption. This makes them the most bioavailable antioxidants known to science.

To learn more, read the patient handout here and check out the dosing guidelines here.

 

*Always ask your physician before starting this or any supplement protocol. The information on this page does not serve as medical advice. Although probiotics are generally well tolerated, these practitioner-grade products should be used with caution in elderly, immunocompromised, toxic and infected (including Lyme, Candida, GI) individuals. A strong die-off reaction is possible even at a low dose in these cases. Consult your physician prior to purchase.

“Probiotics are recognized for their long history of safe use. However, consumption in large amounts under immune-compromised state may raise several safety concerns.” (source) “In 2011, a report was released by the Agency for Healthcare Research and Quality (AHRQ) based on research sponsored by the National Institutes of Health and the FDA and conducted by the Southern California Evidence-based Practice Center reviewing the safety of probiotics. The authors of the report concluded that, although the existing probiotic clinical trials reveal no evidence of increased risk, ‘the current literature is not well equipped to answer questions on the safety of probiotics in intervention studies with confidence.’” (source)